Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AstraZeneca < Previous 1 2 3 4 5 6 Next > ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy October 01, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer September 26, 2024 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial September 23, 2024 From AstraZeneca Via Business Wire Tickers AZN FLUMIST approved for self-administration in the US September 20, 2024 From AstraZeneca Via Business Wire Tickers AZN FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis September 18, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial September 16, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial September 15, 2024 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases September 13, 2024 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial September 09, 2024 From AstraZeneca Via Business Wire Tickers AZN Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial September 08, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024 September 03, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery August 16, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US August 15, 2024 From AstraZeneca Via Business Wire Tickers AZN Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial July 29, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca’s H1 and Q2 2024 Financial Results July 25, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial June 25, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer June 17, 2024 From AstraZeneca Via Business Wire Tickers AZN CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial June 16, 2024 From AstraZeneca Via Business Wire Tickers AZN FARXIGA approved in the US for the treatment of pediatric type-2 diabetes June 12, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer June 10, 2024 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial June 02, 2024 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo June 02, 2024 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy June 02, 2024 From AstraZeneca Via Business Wire Tickers AZN Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial May 27, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA) May 23, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024 May 22, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030 May 21, 2024 From AstraZeneca Via Business Wire Tickers AZN New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease May 19, 2024 From AstraZeneca Via Business Wire Tickers AZN CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial May 02, 2024 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio May 01, 2024 From AstraZeneca Via Business Wire Tickers AZN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.